SHR0302 for UC Met Trial Endpoints
stevepb / Pixabay

SHR0302 for UC Met Trial Endpoints

  Since its inception, biopharmaceutical company Reistone Biopharma Co. Ltd. ("Reistone") has worked to develop treatment options for patients with immuno-inflammatory and autoimmune conditions. Most recently, their drug candidate SHR0302,…

Continue Reading SHR0302 for UC Met Trial Endpoints